EGFR and non-small cell lung carcinoma: In conclusion, this systematic review demonstrated that the addition of VEGF/VEGFR inhibitors could reduce the incidence of drug-induced ILD at any grade caused by EGFR-TKI in patients with NSCLC, but not in grade ≥ 3.